This table calculates osmolarity when formulating IV nutrient therapy (IVNT) solutions. It allows entry of nutrient components and automatically calculates the total volume and osmolarity of selected nutrients and diluents. Maintaining osmolarity within safe ranges helps minimize risks such as hemolysis and phlebitis. The tool also recommends candidate diluents and volumes to keep the solution isotonic or within acceptable hypertonic limits.
Guidance is included for pH correction with sodium bicarbonate, particularly for complex mixtures such as the Myers’ Cocktail. A suggested administration sequence is outlined, starting with a “Warm‑Up” phase (for example, glutathione), followed by the Myers’ Cocktail, and ending with a “Cool‑Down” phase (for example, alpha‑lipoic acid).
| Order | Medication | Classification | mg/mL | pH | Rec Dosage | mL | mOsm/mL | Total mOsm | Description |
|---|---|---|---|---|---|---|---|---|---|
| 1. Warm‑Up | Glutathione (Given separately) |
Antioxidant | 200 | 6.5 | 600–2,000 mg | 1.2 | 0.00 |
Administer glutathione with 10 mL normal saline (N/S) as a slow IV push over ~2 minutes. Often combined with Laennec and diclofenac sodium (Declage). Indications: Antioxidant support, detoxification, immune modulation, neuroprotection, and skin health; supports oxidative stress reduction and hepatic function; may serve as an adjunct during cancer recovery by mitigating chemotherapy‑induced toxicity. Contraindications and cautions: Asthma (bronchospasm risk), hypersensitivity, pregnancy, and lactation (safety not established). Use cautiously with chemotherapy (potential interaction), iron overload disorders, and renal dysfunction. |
|
| 2‑1. Myers’ Cocktail Components | Vitamin C (Ascorbic Acid; C₆H₈O₆) | Vitamin (acidic form) & antioxidant | 500 | 6.61 | 1–100 | 5.34 | 0.00 |
Do not co‑administer with selenium or multi‑mineral formulations because of potential adverse interactions. Suggested remedies for complications from high‑dose IV vitamin C:
Indications: mean corpuscular hemoglobin (↓ MCH), mean corpuscular hemoglobin concentration (↓ MCHC), and mean corpuscular volume (↑ MCV). MorePhysiology & saturation: Plasma vitamin C saturates (~70–80 µM/L) at ~200 mg daily intake. Higher doses increase urinary excretion once renal reabsorption thresholds are exceeded (~1.4 mg/dL or ~80 µM). Total body stores of ~1,500 mg are required for optimal saturation; deficiency symptoms (for example, scurvy) appear when stores fall below ~300 mg (~10 mg/day intake or less). Potential adverse effects: High oral doses may cause osmotic diarrhea or gastrointestinal discomfort. With large IV doses, monitor for oxalate nephropathy in patients with renal dysfunction. Clinical rationale: The acidic form can be useful for high‑dose IV therapy but may increase the risk of vein irritation unless buffered. Monitor pH in large‑dose protocols. Cautions and contraindications:
|
|
| Sodium Ascorbate (C₆H₇NaO₆) | Vitamin (buffered form) | 500 | 7.20 | 1–100 mL | 4.92 | 0.00 |
A buffered form of vitamin C with higher pH that may reduce vein irritation. Commonly used in high‑dose IV vitamin C protocols to improve tolerance. |
||
| MgSO₄ | Mineral | 100 | 6.8 | 1–20 | 0.424 | 0.00 | Combining with (i) calcium gluconate or (ii) thioctic acid may cause precipitation; if used together, administer immediately. | ||
| Vitamin B1 (Thiamine; Fursultiamine) | Vitamin | 100 | 2.5–4.5 | 1–2 | 2.22 | 0.00 | |||
| Vitamin B2 (Riboflavin) | Vitamin | 10 | 5–6 | 1–2 | 0.345 | 0.00 | |||
| Vitamin B3 (Niacin) | Vitamin | 100 | 5–7 | 1–2 | 1.22 | 0.00 | |||
| Vitamin B5 (Dexpanthenol) | Vitamin | 250 | 5.48 | 1–4 | 1.931 | 0.00 | |||
| Vitamin B6 (Pyridoxine) | Vitamin | 50 | 4.21 | 1–4 | 0.473 | 0.00 | |||
| Vitamin B12 (Cyanocobalamin) | Vitamin | 1 | 4.5–5 | 1–2 | 0.183 | 0.00 | |||
| 2‑2. Suitable for mixing with Myers’ Cocktail | Glycyrrhizinate (Hishiphagen‑C) | Herbal extract | 23 | 6.9 | 10–100 | 0.298 | 0.00 |
May increase blood pressure: glycyrrhizinate; L‑carnitine. Incompatible with multi‑mineral formulations. Supports hepatic protection (lowers AST/ALT, stabilizes hepatocytes), modulates immunity (reduces IL‑6, TNF‑α), exhibits antiviral activity (HBV, HCV, influenza, herpes), enhances antioxidant defenses and adrenal support (prolongs cortisol), and protects gastric mucosa and skin. Caution: Potential for sodium retention and hypokalemia; avoid in hypertension, kidney disease, or prolonged use. |
|
| Ginkgo leaf dry extract | Herbal extract | 3.5 | 6.39 | — | 0.895 | 0.00 |
May decrease blood pressure: ginkgo, arginine, and magnesium sulfate (via vasodilation). |
||
| Laennec (Human Placenta Hydrolysate) | Regenerative therapy | 7.8 | 6.5 | 1–8 | 0.288 | 0.00 |
Supports liver regeneration, wound healing, immune modulation, and skin rejuvenation; rich in peptides, amino acids, and growth factors. Caution: Avoid in hormone‑sensitive conditions, pregnancy, or a history of hypersensitivity. Regulatory restrictions may apply. |
||
| Dipeptiven (L‑alanyl‑L‑glutamine) | Amino acid | 0.2 | 5.79 | 50 mL | 0.921 | 0.00 |
For acute gastroenteritis, consider 110 mL N/S with Dipeptiven and 1–2 ampoules of Laennec. MoreGlutamine depletion may lead to muscle wasting, mood disturbance, hyperammonemia, and impaired gut function. Repletion supports the glucose–glutamine cycle, insulin secretion and sensitivity, fatty acid oxidation, and attenuation of inflammation. It also helps maintain gastrointestinal epithelial tight junctions and may be beneficial in cancer‑associated cachexia. Use caution or avoid in renal or hepatic insufficiency or metabolic acidosis. |
||
| Arginine | Amino acid | 600 | 5.25 | 2–25 mL | 4.73 | 0.00 |
N/S 110 mL with 150 g of arginine and vitamin B1 – muscle recovery and energy support. N/S 110 mL with 150 g of arginine and zinc – male sexual health and cold extremities. N/S 110 mL with 150 g of arginine, zinc, and magnesium – migraine support. Note: Arginine may exacerbate herpes simplex and herpes zoster. |
||
| L‑aspartate‑L‑ornithine | Amino acid | 300 | 6.50 | 1–10 mL | 1.800 | 0.00 | |||
| S‑adenosyl‑L‑methionine (SAMe) | Methyl donor / amino acid derivative | 20 | 7.71 | 5–10 mL | 0.426 | 0.00 |
Incompatible with ginkgo biloba and calcium gluconate. |
||
| Apo‑choline | Lipotropic | 250 | 6.7 | 1–5 | 1.915 | 0.00 | |||
| L‑carnitine | Amino acid | 200 | 6.47 | 5–10 mL | 2.158 | 0.00 | |||
| N‑acetylcysteine (NAC) | Antioxidant | 100 | 6.83 | 1–9 | 1.353 | 0.00 | |||
| 2‑3. Caution required when mixing with Myers’ Cocktail | Calcium gluconate | Mineral | 100 | 6.59 | 1–4 | 0.29 | 0.00 |
Combining with magnesium may cause precipitation; if used together, administer immediately. Combination with sodium bicarbonate is generally discouraged. In cases of significant vascular irritation, some protocols add 2 mL of sodium bicarbonate for immediate use. |
|
| Zinc | Mineral | 1 | 3.1 | 1–10 | 0.025 | 0.00 |
Incompatible with sodium bicarbonate. Injections may cause pain due to acidity; for vascular pain, 2 mL of 2% lidocaine is sometimes used for relief. Usually mixed with N/S or included as part of the Myers’ Cocktail. N/S 110 mL with 150 g of arginine and zinc. N/S 250 mL with zinc, magnesium, and vitamin B12. MoreSupports immune function, wound healing, antioxidant defenses, hormonal balance, neurological health, gut integrity, and metabolic regulation. May support cochlear function and tinnitus in zinc‑deficient individuals by promoting cochlear health, neurotransmitter balance, and antioxidant protection. Caution: Excess zinc can cause copper deficiency, nausea, or GI discomfort; use cautiously in renal impairment or during high‑dose, long‑term therapy. |
||
| 3. Cool‑Down | Thioctic acid (alpha‑lipoic acid) (Given separately) |
Antioxidant lipid | 30 | 7.1 | 100–600 mg | 0.15 | 0.00 |
Combining with magnesium may cause precipitation; if used together, administer immediately. Typical approach: 300–600 mg thioctic acid plus fursultiamine in 100 mL N/S, IV infusion. Example: 500 mL D5W mixed with alpha‑lipoic acid, infused over ~15 minutes. Sometimes combined with 100 mL acetaminophen and vitamin B12 for analgesic support. |
|
| Others | Selenium (Se) (Given separately) |
Mineral & antioxidant | 0.5 | 6.2 | 100–200 mcg | 0.002 | 0.00 |
Forms inactive complexes with certain metals (for example, mercury), reducing toxicity. Administration may be IV or oral alongside chelators. Consider monitoring selenoproteins and overall redox status. |
|
| Multi‑mineral | Mineral | N/A |
Do not combine with (i) glycyrrhizinate, (ii) sodium bicarbonate, or (iii) vitamin C. Combination with amino acids is often preferable, which may reduce pain and precipitation (for example, multi‑mineral mixed with an arginine solution). Injections may cause pain due to acidity; for vascular pain, 2 mL of 2% lidocaine is sometimes used for relief. |
||||||
| Calcium‑disodium EDTA chelation | Chelator | 200 | 6.5 | 1–3 g | 0.70 | 0.00 |
Particularly effective for lead chelation and may assist mild to moderate renal dysfunction by reducing lead burden. May reduce iron overload to some extent. For mercury, combine with alpha‑lipoic acid, glutathione, and selenium (separately) for broader heavy‑metal detoxification. EDTA dose (mg) = (50 mg/kg) × LBW × CrCl / 100
MoreWhy Ca‑EDTA (vs. Na‑EDTA)? Calcium‑disodium EDTA reduces the risk of hypocalcemia associated with Na‑EDTA. Ca‑EDTA still binds select heavy metals without significant calcium chelation. Typical protocol: Often mixed with lidocaine, vitamin C, MgSO₄, B5, B6, and B12 in a single IV bag. Adjust volume/diluent to ensure safe osmolarity and pH. Infuse slowly over 1–2 hours with vital‑sign monitoring. Measuring heavy metals: Methods include whole blood levels, RBC metals, 24‑hour urine, or post‑challenge urine after a chelator dose. Interpret results using standard references. |
||
| Thymosin α1 | Immunomodulator | N/A | ~6.0 | 1.6 mg (typical) or per protocol | 0.00 | 0.00 |
MoreRoute: SQ or IM injection (not typically IV). Often used 2–3 times per week for immune modulation. Clinical notes: Enhances T‑cell function, supports antiviral defenses, and modulates immune balance; monitor for injection‑site reactions. |
||
| Viscum album (mistletoe extract) | Immunomodulator | N/A | ~6.0 | Dose by brand/protocol (1–20 mg SC) | 0.00 | 0.00 |
Route: Typically subcutaneous. Injection‑site reaction: A local dermal response < 5 cm in diameter is generally considered normal and may indicate the desired immunologic activity. MoreCommon brands: Iscador®, Abnoba Viscum®, Helixor®. Clinical notes: Used as adjunctive therapy in oncological or immunomodulatory protocols; may improve quality of life and reduce adverse effects from chemotherapy or radiation. |
||
| IV iron (Monofer®, Ferinject®) | Iron supplement | 50 | 6.5–7.0 | 500–1,000 mg | 2.00 | 0.00 |
Assessment: Confirm iron deficiency (low ferritin, high TIBC, microcytosis) versus inflammation, renal disease, or hypometabolic states before dosing. Calculate total dose via the Ganzoni formula: Required iron (mg) = BW (kg) × (Target Hb − Actual Hb) (g/dL) × 2.4 + 500 mg (stores) MoreIndications: Rapid correction of iron‑deficiency anemia, including in CKD, heavy menstrual bleeding, or postpartum anemia. Contraindications: Hypersensitivity to iron complexes, active infection, or iron overload (for example, hemochromatosis). Use caution in acute inflammatory conditions. Clinical notes:
|
||
| Omegaven (omega‑3 PUFA) | Lipid emulsion | 100 | 8.0 | 100–200 mL | 0.30 | 0.00 |
MoreClinical uses: Often employed in parenteral nutrition; may be beneficial in certain oncologic settings and for anti‑inflammatory support. Cautions: Platelet aggregation disorders, severe hyperlipidemia, or concern for fat overload syndrome. Monitor triglycerides and coagulation parameters. Infusion: Administer as a separate infusion or within TPN; not mixed with the Myers’ Cocktail. Infuse over several hours. |
||
| Finehera (Human Placenta Hydrolysate) |
Regenerative therapy | 7.8 | 6.5 | 1–8 mL | 0.288 | 0.00 | |||
| Ferinject (Ferric carboxymaltose) |
Iron supplement | 50 | 6.5–7.0 | 500–1,000 mg | 2.0 | 0.00 | |||
| Diluents | Sodium bicarbonate | Alkalinizer | 84 | 8.3 | 1–2 | 1.621 | 0.00 |
Incompatibilities with sodium bicarbonate include:
|
|
| Diluent | 9 | 6 | — | 0.296 | 0.00 | ||||
| Results and Recommendations | Total | — | — | — | — | 0.00 | — | 0.00 | |
| Final Osmolarity | 0.00 mOsm/L | ||||||||
| Recommended Diluent and Volume | N/S: 0 mL - 0 mL | SterileWater: 0 mL - 0 mL | 5DS: 0 mL - 0 mL | 5DW: 0 mL - 0 mL | Half Saline: 0 mL - 0 mL | Amino Acid 5%: 0 mL - 0 mL | Amino Acid 10%: 0 mL - 0 mL | ||||||||
| Final pH | 7.00 | ||||||||
| Recommended Sodium Bicarbonate | 0 mL | ||||||||
A color‑coded guide is integrated to indicate osmolarity levels of calculated solutions. The scheme ranges from red (high risk due to hypo‑ or hypertonicity) to green (isotonic), providing immediate feedback on suitability for peripheral or central administration.
| Osmolarity Range (mOsm/L) | Color | Interpretation |
|---|---|---|
| < 200 | Red | Hypotonic — high risk; adjust diluent volume. |
| 200–239 | Yellow | Hypotonic — use with caution; monitor for hemolysis. |
| 240–340 | Green | Isotonic — generally suitable for peripheral administration. |
| 341–500 | Yellow | Slightly hypertonic — use with caution; monitor for phlebitis. |
| 501–900 | Orange | Hypertonic — central venous access recommended. |
| > 900 | Red | Highly hypertonic — high risk; adjust diluent volume. |
This document consolidates and summarizes dispersed information. It does not guarantee accuracy or assume responsibility for patient outcomes. Clinicians remain solely responsible for decisions and outcomes when following this guidance.
© 2013 Hyunsuk Frank Roh, MD. All Rights Reserved.
Project nGene.org® is a registered trademark.
nGene Hemodynamic Research Center